Nov 8, 2024
 in 
Hot Stocks 🔥

Novo Nordisk Coming Out Of 9 Month Low | Nemo

Name of opportunity: 👀

Novo Nordisk A/S

Stabilising: ⚖️

On Wednesday, Novo Nordisk shared sales growth for Wegovy, its injectable weight loss drug, which may be at least in part a result of the drug becoming available in more countries worldwide. But Novo Nordisk’s sales growth guidance has also narrowed - while the company had previously predicted a figure of 22%-28%, the new figure is 23%-27%, with a lower upper limit. While the stock initially jumped by 8%, it then fell yesterday to a 9 month low - from which it has begun to recover.

How hot is this investment opportunity? 🔥🔥🔥

Check out the Novo Nordisk on Nemo Money. Analysts predict the price of Novo Nordisk A/S might increase from $106.19 to $151.41 in the next 12 months. If you invested $1000, you might profit $437.07.

Part of the reason for this optimistic outlook from analysts might be because of the news that Novo Nordisk’s new drug CagriSema is performing well in trials. CagriSema is a combination treatment using both semaglutide (the ingredient in Wegovy) and cagrilintide - an ingredient that targets different receptors in the body. Trial data released yesterday indicated that CagriSema may be able to help people lose up to 25% of their body weight, a higher percentage than any other drug on the market. 

Europe’s biggest company by market cap: 🇪🇺

The Danish pharmaceutical business has the biggest market cap in Europe, thanks in part to the runaway success of its drugs Wegovy and Ozempic (another semaglutide treatment which is prescribed for diabetes). Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals.

Which neme?: 🔍

‘Top Biotech Stocks’, ‘Pharma’, ‘Future Tech: World Changing Ideas’ and ‘This Week’s Earnings’ 

Download Nemo to check out Novo Nordisk. New users can access our registration bonus. We'll give you 50% of what you top up your account with (maximum bonus $50, terms and conditions apply).

Han Tan

Han Tan is a seasoned financial journalist and news presenter renowned for his expertise in global markets. With a career highlighted by interviews with prominent figures and recognition from major media outlets like CNN and Reuters, he delivers insightful analysis on market news and macroeconomic trends to clients and international audiences. Han's sharp commentary on currencies, stocks, and commodities is familiar to viewers of Bloomberg TV Malaysia, BFM 89.9, and NTV7, cementing his sterling reputation in the industry.